

PRESS RELEASE

2D-BioPAD Partners Meet in Kuopio, Finland to Advance the Next Phase of Alzheimer's Point of Care Testing

Kuopio, Finland | November 10-11, 2026

The 7th project meeting of the 2D-BioPAD project took place on 10-11 November 2026 in Kuopio, Finland, bringing together partners from across Europe to review progress, discuss key challenges, and plan the next steps towards the early detection and monitoring of Alzheimer's disease.

Hosted by the University of Eastern Finland, the two-day meeting focused on the development and validation of the 2D-BioPAD Point-of-Care decision-support tool, progress in clinical studies, and preparations for the next phase of the project.

During the first day, partners shared updates on the development of the project's graphene-based biosensors, including their performance, testing results, and integration into PoC prototypes. The team has down significant progress, reaching sensitivity in the range of a few pg/mL for several AD biomarkers. Discussions also covered the use of artificial intelligence to improve the technology, as well as progress on the decision support software, the mobile user interfaces, and other components needed to make 2D-BioPAD ready for clinical use.

A key focus was the discussion on technical validation results from real biological samples (CSF and Plasma) in the context of the retrospective clinical pilot study and preparations for upcoming clinical activities. Partners discussed the next steps for clinical testing, including sample collection and plans to involve healthcare professionals in evaluating the devices' usability. These activities will help assess the technology's performance and its potential use in real healthcare settings.

The second day included a visit to UEF's labs, providing an opportunity for partners to explore the host institution's research facilities and potential future collaborations. Discussions continued with a focus

Funded by the European Union under GA no. 101120706 (2D-BioPAD). Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union or CNECT. Neither the European Union nor the granting authority can be held responsible for them.

Funded by the European Union

on clinical validation, regulatory requirements, and the technical, clinical, and ethical aspects of evaluating the tool.

Beyond scientific and clinical progress, partners explored how project results can create long-term impact. Particular attention was given to strengthening collaboration with relevant initiatives, planning future outreach activities (such as policy, regulatory and standardization workshops), and exploring opportunities to bring the 2D-BioPAD technology closer to the market. Discussions also covered business planning, potential distribution strategies, and the long-term use of project results.

The meeting also served as a key milestone in preparations for the project's second review. Partners evaluated progress towards strategic objectives and key performance indicators, updated plans for the next project period, and reinforced their shared commitment to delivering meaningful outcomes for people affected by Alzheimer's disease.

As the project moves forward, 2D-BioPAD continues to demonstrate the value of European collaboration in tackling one of society's most pressing health challenges. By bringing together expertise from research, healthcare, and industry, the consortium is working towards a future where earlier and more accessible diagnosis can help improve quality of life for patients and support more sustainable healthcare systems across Europe.

The consortium renewed their rendezvous for spring 2027 to continue pushing the boundaries of 2D-based biosensors for challenging healthcare applications.

Funded by the European Union under GA no. 101120706 (2D-BioPAD). Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union or CNECT. Neither the European Union nor the granting authority can be held responsible for them.

Funded by the European Union